<DOC>
	<DOCNO>NCT00421642</DOCNO>
	<brief_summary>This open-label study 20 patient design demonstrate safety , tolerability preliminary evidence benefit adalimumab treatment subject Ulcerative Colitis , patient never receive anit-TNF agent lose response develop intolerance previous infliximab therapy .</brief_summary>
	<brief_title>Open-Label Adalimumab Ulcerative Colitis Patients</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Inclusion Criteria 1 . Males females 18 year age old 2 . Female subject must utilize highly effective method birth control throughout study 70 day study completion , female subject must childbearing potential , defined postmenopausal least two year , surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy ) . 3 . A diagnosis UC great 3 month . 4 . UC diagnosis confirm endoscopy exclusion infectious cause . 5 . Active ulcerative colitis Mayo Clinic Score ( see Appendix C ) 6 12 point moderatelytoseverely active disease sigmoidoscopy ( endoscopic subscore least 2 ) despite concurrent treatment corticosteroid , and/or azathioprine 6 mercaptopurine and/or 5aminosalicylatecontaining medication . Patients previously respond could tolerate corticosteroid ( within past 18 month ) , azathioprine 6 mercaptopurine ( within past 5 year ) , 5 aminosalicylatecontaining medication ( within past 18 month ) require take concurrent therapy enrollment . 6 . Either antiTNF agent na√Øve previous clinical response infliximab therapy UC subsequent loss response AND/OR unable tolerate infliximab therapy UC due acute delayed reaction , define investigator . 7 . Subjects must able willing give write informed consent comply requirement study protocol . 8 . Adequate cardiac , renal hepatic function determine principal investigator demonstrate screen laboratory evaluation , questionnaire , physical examination result within normal limit . Exclusion Criteria 1 . History cancer lymphoproliferative disease successfully completely treat squamous cell basal cell carcinoma skin . 2 . Subjects history Listeria , Hepatitis B infection , central nervous system ( CNS ) demyelinate disease , human immunodeficiency virus ( HIV ) history previously untreated TB . See Appendix B . 3 . Subjects Crohn ? Disease 4 . Subjects symptomatic obstructive stricture 5 . Subjects subtotal colectomy ileorectostomy colectomy ileoanal pouch , Kock pouch , ileostomy ulcerative colitis planning subtotal colectomy colectomy within 8 week start study medication . 6 . Subjects currently receive total parenteral nutrition ( TPN ) . 7 . Any investigational chemical agent past 30 day 5 halflives prior screen ( whichever longer ) . Patients previously treat infliximab respond , become intolerant infliximab lose response , treat &gt; /= 4 week last infliximab dose . 8 . Antibiotic treatment systemic infection within 3 week prior screen . 9 . Female subject pregnant breastfeeding . 10 . History clinically significant drug alcohol abuse prior year . 11 . Poorly control medical condition , include limited diabetes document history recurrent infection cerebrovascular accident ( within 3 month ) . 12 . Subjects cyclosporine tacrolimus within 4 week screen . 13 . Subjects methotrexate within 4 week screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>